Mitapivat
CAS: 1260075-17-9
Ref. 3D-KAC07517
| 2mg | 295.00 € | ||
| 5mg | 461.00 € | ||
| 10mg | 656.00 € | ||
| 25mg | 1,016.00 € | ||
| 50mg | 1,323.00 € |
Product Information
- N-(4-{[4-(Cyclopropylmethyl)-1-piperazinyl]carbonyl}phenyl)-8-quinolinesulfonamide
- N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Mitapivat is an aromatase inhibitor that has been shown to be effective in the treatment of breast cancer. It is administered orally and inhibits the production of estrogen. Mitapivat has been shown to have a specific effect on epithelial-mesenchymal transition in cancer tissues, which may contribute to its anticancer activity. Mitapivat also has pharmacological activity, such as inhibiting the production of lipids and proteins in the liver. Mitapivat can also cause adverse effects on red blood cells and renal function, including a decrease in glomerular filtration rate. The drug causes changes in redox potential and energy metabolism, leading to an increase in atp levels and a reduction in blood disorders. In vivo studies have shown that mitapivat can inhibit tumor growth by suppressing protein synthesis, cell proliferation, and angiogenesis.
Chemical properties
Technical inquiry about: 3D-KAC07517 Mitapivat
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
